-- 
GlaxoSmithKline, IAG, Smurfit Kappa: U.K., Irish Equity Preview

-- B y   B l a n c h e   G a t t
-- 
2011-05-06T06:27:35Z

-- http://www.bloomberg.com/news/2011-05-05/glaxosmithkline-iag-smurfit-kappa-u-k-irish-equity-preview.html
The following is a list of companies
that may have unusual share-price changes in U.K. and Irish
markets. Stock symbols are in parentheses and prices are from
the last market close.  The benchmark FTSE 100 Index fell 64.09 points, or 1.1
percent, to 5,919.98. The FTSE All-Share Index dropped 1 percent
while Ireland’s ISEQ Index fell 0.6 percent.  GlaxoSmithKline Plc (GSK)  : Chief Executive Officer
 Andrew Witty  said all options are open in the long term for the
Viiv Healthcare Ltd. venture, which specializes in HIV
treatments. The stock gained 0.3 percent to 1,310 pence.  International Consolidated Airlines Group SA (IAG LN): The
group formed by the merger of British Airways and Spain’s Iberia
posted a first-quarter profit after taxes of 33 million euros
($48 million) compared with a 243 million-euro loss a year ago.
The stock rose 2.8 percent to 246 pence.  Lancashire Holdings Ltd. (LRE)  : The property insurer
that first sold shares in  London  in 2005 said net income in the
first quarter rose 4.9 percent to $8.6 million from $8.2 million
a year earlier. The shares gained 0.1 percent to 640 pence.        Royal Bank of Scotland Group Plc (RBS)  : Britain’s
biggest government-owned lender reported a wider-than-estimated
first-quarter loss on charges for using a government insurance
program for its riskiest assets. The shares dropped 2.9 percent
to 40.48 pence.  Smurfit Kappa Group Plc (SKG)  : Europe’s largest
containerboard maker said first-quarter operating profit
excluding one-time items rose 69 percent to 148 million euros.
The company said it should see earnings growth and
“meaningful” debt paydown even as costs rise faster than
expected. The shares dropped 2.3 percent to 8.69 euros.  To contact the reporter on this story:
Blanche Gatt in London at 
 bgatt@bloomberg.net   To contact the editor responsible for this story:
Colin Keatinge at 
 ckeatinge@bloomberg.net  